Skip to main content

Table 1 Clinical variables in the training and testing sets

From: Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma

Variables Total set (n = 372) Training set (n = 186) Testing set (n = 186) p value Methods
Survival time (days) 555.0 (232.25–1085.0) 555.5 (324.0–1088.25) 555.0 (320.0–1085.75) 0.94 Mann–Whitney
U test
Vital status
 Live 246 (66.13%) 117 (62.90%) 129 (69.35%) 0.189 χ2 test
 Dead 126 (33.87%) 69 (37.10%) 57 (30.65%)
Age (years)  
 ≤ 65 234 (62.9%) 120 (64.52%) 114 (61.29%) 0.52 χ2 test
 > 65 138 (37.1%) 66 (35.48%) 72 (38.71%)
Gender
 Male 251 (37.1%) 124 (66.67%) 127 (68.28%) 0.74 χ2 test
 Female 121 (32.53%) 62 (33.33%) 59 (31.73%)
BMI (kg/cm2)
 < 25 178 (47.85%) 85 (45.70%) 93 (50.00%) 0.35 χ2 test
 ≥ 25 157 (42.20%) 85 (45.70%) 72 (38.71%)
 NA 37 (9.95%) 16 (8.6%) 21 (11.29%)
Histological grade
 G1 55 (14.78%) 29 (15.59%) 26 (13.98%) 0.925 χ2 test
 G2 178 (47.85%) 86 (46.24%) 92 (49.46%)
 G3 122 (32.8%) 61 (32.8%) 61 (32.80%)
 G4 12 (3.23%) 7 (3.76%) 5 (2.69%)
 NA 5 (1.34%) 3 (1.61%) 2 (1.08%)
Clinical stage
 I 172 (46.24%) 86 (46.24%) 86 (46.24%) 0.788 χ2 test
 II 86 (23.12%) 39 (20.97%) 47 (25.27%)
 III 85 (22.85%) 44 (23.66%) 41 (22.04%)
 IV 5 (1.34%) 3 (1.61%) 2 (1.08%)
 NA 24 (6.45%) 14 (1.61%) 10 (5.38%)
T stage
 T1 182 (48.92%) 90 (48.39%) 92 (49.46%) 0.806 χ2 test
 T2 94 (25.27%) 44 (23.66%) 50 (26.88%)
 T3 80 (21.51%) 44 (23.66%) 36 (19.35%)
 T4 13 (3.49%) 7 (3.76%) 6 (3.23%)
 Tx 3 (0.81%) 1 (0.54%) 2 (1.08%)
M stage
 M0 267 (71.77%) 132 (70.97%) 135 (72.58%) 0.593 χ2 test
 M1 4 (1.08%) 3 (1.61%) 1 (0.54%)
 Mx 101 (27.15%) 51 (27.42%) 50 (26.88%)
N stage
 N0 253 (68.01%) 124 (66.67%) 129 (69.35%) 0.467 χ2 test
 N1 4 (1.08%) 1 (0.54%) 3 (1.61%)
 Nx 115 (30.91%) 61 (32.8%) 54 (29.03%)
Adjacent hepatic tissue inflammation extent
 None 118 (31.72%) 64 (34.41%) 54 (29.03%) 0.12 χ2 test
 Mild 100 (26.88%) 48 (25.81%) 52 (27.96%)
 Severe 17 (4.57%) 4 (2.15%) 13 (6.99%)
 NA 137 (36.83%) 70 (37.63%) 67 (36.02%)
Child–pugh classification grade
 A 217 (58.33) 103 (3.76%) 114 (61.29%) 0.09 χ2 test
 B 21 (5.65%) 7 (3.76%) 14 (7.53%)
 C 1 (0.27%) 0 (0.00%) 1 (0.54%)
 NA 133 (35.75%) 76 (40.86%) 57 (30.65%)
AFP (ng/ml)
 < 300 213 (57.26%) 103 (55.38%) 110 (59.14%) 0.76 χ2 test
 ≥ 300 65 (17.47) 34 (18.28%) 31 (16.67%)
 NA 94 (25.27%) 49 (26.34%) 45 (24.19%)
Fibrosis ishak score
 0-No fibrosis 75 (20.16%) 44 (23.66) 31 (16.67%) 0.38 χ2 test
 1,2-Portal fibrosis 31 (8.33%) 16 (8.6%) 15 (8.06%)
 3,4-Fibrous speta 28 (7.53%) 15 (8.06) 13 (6.99%)
 5-Nodular formation and incomplete cirrhosis 9 (2.42%) 4 (2.15%) 5 (2.69%)
 6-established cirrhosis 70 (18.82%) 28 (15.05%) 42 (22.58%)
 NA 159 (42.74%) 79 (42.47%) 80 (43.01%)
Hepatic carcinoma risk factor
 No history of primary risk factors 86 (23.12%) 46 (24.73%) 40 (21.51%) 0.14 χ2 test
 Alcohol consumption 113 (30.38%) 57 (30.65%) 56 (30.11%)
 Hepatitis B 100 (26.88%) 42 (22.58%) 58 (31.18%)
 Hepatitis C 54 (14.52%) 24 (12.90%) 30 (16.13%)
 Non-Alcoholic fatty liver disease 20 (5.38%) 16 (8.60%) 4 (2.15%)
 Hemochromatosis 6 (1.61%) 3 (1.61%) 3 (1.61%)
 Others 20 (5.38%) 10 (5.38%) 10 (5.38%)
 NA 18 (91.13%) 8 (4.3%) 10 (5.38%)
Vascular invasion
 None 207 (55.65%) 98 (52.69%) 109 (58.06%) 0.33 χ2 test
 Mico 93 (25.00%) 45 (24.19%) 48 (25.81%)
 Macro 16 (4.30%) 10 (5.38%) 6 (3.23%)
 NA 56 (15.05%) 33 (17.74%) 23 (12.37%)
Histological diagnosis
 Hepatocellular carcinoma 358 (96.24%) 178 (95.70%) 180 (96.77%) 0.69 χ2 test
 Cholangiocarcinoma 7 (1.88%) 4 (2.15%) 3 (1.61%)
 Clear cell carcinoma 4 (1.08%) 3 (1.61%) 1 (0.54%)
 Fibrolamellar carcinoma 3 (0.81%) 1 (0.54%) 2 (1.08%)